Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Quince Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-10-18).
- Leadership changes: the latest reported is Dirk Thye, Chief Executive Officer and Chief Medical Officer (Form 8-K filed 2026-10-09). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names James B. Tananbaum (filed 2026-10-14).
Who is behind it
Quince Therapeutics, Inc.: incorporated in Delaware; business address in New Haven, Connecticut; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-10-14).
Officers and directors, each with the role and the filing that names them:
- Dirk Thye: Executive Officer, Director (Form D, 2026-06-11)
- Brigette Roberts: Executive Officer, Director (Form D, 2026-06-11)
- Charles Ryan: Executive Officer (Form D, 2026-06-11)
- Brendan Hannah: Executive Officer (Form D, 2026-06-11)
- David Lamond: Director (Form D, 2026-06-11)
- Christopher Senner: Director (Form D, 2026-06-11)
- June Bray: Director (Form D, 2026-06-11)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-14 | James B. Tananbaum | 6% |
| Schedule 13G, 2026-10-14 | Perceptive Advisors LLC | 8.4% |
| Schedule 13G, 2026-08-14 | Cormorant Asset Management, LP | 9.99% |
| Schedule 13G, 2026-08-14 | Ikarian Capital, LLC | 9% |
| Schedule 13G/A, 2026-08-14 | Nantahala Capital Management, LLC | 0% |
| Schedule 13G, 2026-08-14 | Balyasny Asset Management L.P. | 9.99% |
| Schedule 13G, 2026-08-04 | Squadron Master Fund LP | 5.6% |
| Schedule 13G, 2026-06-10 | Integrated Core Strategies (US) LLC | 7.2% |
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-09 | Dirk Thye | Chief Executive Officer and Chief Medical Officer | departed | 2026-10-08 |
| Form 8-K, 2026-10-09 | Brigette Roberts | Chief Executive Officer | appointed | 2026-10-08 |
| Form 8-K, 2026-10-09 | John Militello | Chief Financial Officer | appointed | |
| Form 8-K, 2026-10-09 | Keith Fandrick | Chief Operating Officer | appointed | |
| Form 8-K, 2026-10-02 | Catherine Bonuccelli | Director | appointed | |
| Form 8-K, 2026-05-18 | Brigette Roberts | Director | appointed |
Money raised
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-06-11 | $114.72M | $186.42M |
| Form D, 2026-06-11 | $0 | $7.39M |
| Form D, 2025-07-01 | $11.49M | $21.90M |
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-09-14); completed an acquisition (2026-05-18).
Related pages
Funding and filing historyLeadership changes5%+ holdersCourt record
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
Permanent URL:
https://mentionfox.com/who-owns/quince-therapeutics-incLast updated 2026-10-18
Primary record: Schedule 13G, 2026-10-14 · Form D, 2026-06-11 · Form 8-K, 2026-10-09 · Form 8-K, 2026-10-02
Who owns Quince Therapeutics, Inc.? Owners, funding and legal record. MentionFox, 2026-10-18. https://mentionfox.com/who-owns/quince-therapeutics-inc